A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results published in Annals of the Rheumatic Diseases. “Ivarmacitinib (formerly SHR0302), an orally administered, highly selective JAK1 inhibitor, exhibits potency and selectivity for JAK1 that is over 10-fold for JAK2,
Traumatic posterior shoulder dislocations are commonly associated with a posterior labral tear and an impaction fracture involving the anterior humeral head referred to as a…
nd Data. PSI in scoliosis affects patient quality of life. While other correction methods have reported a high correction rate for the main thoracic curve…
No link was found between Competitive Bidding Program implementation and changes in supplemental oxygen use or clinical outcomes in a population of Medicare beneficiaries with…
Among adults in California, those who identified as multiracial had greater lifetime and current asthma prevalences vs. the monoracial populations they shared identities with, according…
Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer-reviewed rheumatology journal of the rheumatic diseases.
research and clinical care. The objective of this study was to develop a home QST (HQST) tool-kit that is cost-effective, easy to use, and detects…
The CDC has awarded Weill Cornell Medicine a 5-year, $2.3 million grant to advance equitable access to care for young patients with breast cancer. The…
This post hoc analysis of 2 randomized clinical trials examines whether C-reactive protein estimated response to adalimumab in patients with hidradenitis suppurativa.
Read articles appearing in the print edition of Ocular Surgery News U.S. Edition. Healio is your trusted source for medical news.
